Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
NCT05543928 · OPKO Health, Inc. · PHASE3 · terminated · last registry update 2025-07-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “FDA changed the post-marketing requirement necessitating a new study design and protocol.” | – | Registry record, OPKO Health, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VDR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-15Results posted on the registry: Universitas Sebelas Maret, Vitamin D3 + Antiretroviral (ARV) medications (NCT07553052)
- 2026-07-13Results posted on the registry: Texas Christian University, a drug against VDR (NCT07271316)
- 2026-07-10Phase 3 first posted: Johns Hopkins Bloomberg School of Public Health, a drug against VDR (NCT07695883)
- 2026-07-02Results posted on the registry: Sanofi, Doxercalciferol (GZ427397) + Calcitriol (NCT02859896)
- 2026-07-02Also stopped (terminated): Sanofi, Doxercalciferol (GZ427397) + Calcitriol (NCT02859896)
- 2026-06-24Also stopped (terminated): University Hospital, Bordeaux, a drug against VDR (NCT04067219)
- 2026-06-22Phase 3 first posted: Creighton University, doxercalciferol capsules, Hectorol® + Matched Placebo (Capsules) (NCT07660536)
- 2026-06-22Phase 3 first posted: Alexandria University, Calcipotriol 0.005% gel (NCT07658508)
- 2026-06-15Results posted on the registry: University of South Carolina, a drug against VDR (NCT04981847)
- 2026-06-15Results posted on the registry: AbbVie, Paricalcitol (NCT04064827)
- 2026-06-15Also stopped (terminated): AbbVie, Paricalcitol (NCT04064827)
- 2026-06-12Phase 3 first posted: Tanta University, a drug against VDR (NCT07644520)
- 2026-05-20Phase 3 first posted: University of Ilorin Teaching Hospital, vitamin D 25(OH)D (NCT07598032)
- 2026-05-14Also stopped (suspended): Virginia Commonwealth University, Ergocalciferol Capsules (NCT05259527)
- 2026-05-12Results posted on the registry: HonorHealth Research Institute, Paricalcitol (Zemplar) (NCT03415854)
- 2026-05-08Also stopped (terminated): University of North Carolina, Chapel Hill, Omega-3 fatty acids (fish oil) + Vitamin D3 (cholecalciferol) (NCT03313076)
- 2026-05-07Results posted on the registry: Massachusetts General Hospital, Calcitriol (NCT03748966)
- 2026-04-27Also stopped (suspended): Massachusetts General Hospital, a drug against VDR (NCT04225819)
- 2026-04-23Also stopped (terminated): Melinda Telli, Vitamin D (NCT01472445)
- 2026-04-22Results posted on the registry: HonorHealth Research Institute, Paclitaxel Protein Bound (Abraxane) (NCT03138720)
- 2026-04-17Also stopped (withdrawn): Eli Avisar, MD, Vitamin D3 (NCT02856503)
- 2026-04-13Also stopped (terminated): Dr. B. Catharine. Craven, Rosuvastatin Calcium + Placebo Oral Tablet (NCT03113994)
- 2026-04-03Results posted on the registry: Brigham and Women's Hospital, Omega-3 fatty acid (fish oil) + Fish oil placebo (NCT01633177)
- 2026-04-03Also stopped (terminated): OPKO Health, Inc., Calcifediol Oral Capsule + Placebo oral capsule (NCT03602261)
- 2026-03-31Results posted on the registry: University of Nebraska, a drug against VDR (NCT02553447)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision